The new drug pegozafermin could offer a promising treatment for patients with metabolic dysfunction–associated steatohepatitis, according to a phase 2b multicenter trial.
Pegozafermin is a long-acting glycopegylated analog of fibroblast growth factor 21 (FGF21), a hormone produced mainly in the liver that is important for regulation of glucose and lipid homeostasis. In recent years, researchers have been working to harness the hormone to treat a variety of diseases, including MASH,